Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>As markets reel from the reimposition of tariffs on Mexico and Canada, investors are scrambling for stability in a landscape marked by global trade uncertainty and rising macroeconomic risk.</li><li>While the broader market has faltered, McKesson Corporation, the largest drug distributor in the U.S., has quietly emerged as a defensive standout.</li><li>The company's supply chain resilience, diversified business model, and essential role in healthcare delivery position it as a stock that is potentially insulated from the brunt of economic and policy headwinds.</li></ul>

As markets reel from the reimposition of tariffs on Mexico and Canada, investors are scrambling for stability in a landscape marked by global trade uncertainty and rising macroeconomic risk.While the broader market has faltered, McKesson Corporation, the largest drug distributor in the U.S., has quietly emerged as a defensive standout.The company's supply chain resilience, diversified business model, and essential role in healthcare delivery position it as a stock that is potentially insulated from the brunt of economic and policy headwinds.

Is McKesson Wall Street’s Safe Haven? How This Drug Giant Can Thrive In Uncertain Times!

<ul><li>McKesson Corporation's third-quarter fiscal 2025 earnings call reveals a mix of robust financial performance and strategic advancements, balanced by certain challenges.</li><li>The company achieved an 18% revenue increase to $95.3 billion, with a notable 16% growth in adjusted operating profit, reaching $1.5 billion.</li><li>This performance was bolstered by strong contributions from the U.S. Pharmaceutical and Prescription Technology Solutions segments, underscoring the company's operational strength and its diversified business model.</li></ul>

McKesson Corporation's third-quarter fiscal 2025 earnings call reveals a mix of robust financial performance and strategic advancements, balanced by certain challenges.The company achieved an 18% revenue increase to $95.3 billion, with a notable 16% growth in adjusted operating profit, reaching $1.5 billion.This performance was bolstered by strong contributions from the U.S. Pharmaceutical and Prescription Technology Solutions segments, underscoring the company's operational strength and its diversified business model.

McKesson Corporation: Growth in Prescription Technology Solutions (RxTS) to Solidify Its Competitive Advantage!

Alpha-Centric ESG Research

Kyle Rudden

COVID-19 vaccines figure into Biden's recently-announced COVID-19 response plan, though with a clear emphasis on distribution versus development (as was Trump's focus). Biden's prioritisation of vaccine distribution – and the US$25 billion earmarked for it – is a gift for "cold chain" stocks."Cold chain" refers to a complex temperature-controlled supply chain that is mission-critical to the distribution of COVID-19 vaccines. Critical, because vaccines require consistent ultra-cold storage from manufacture to needle-stick, otherwise those expensive vaccines become medical waste.This Insight looks at cold chain stocks as an investment theme inherent in Biden's COVID-19 plan (see <a href="https://www.smartkarma.com/insights/biden-covid-19-response-plan-overview-of-its-inherent-investment-themes" target="_blank" data-smartkarma-citation="insights:45631" rel="noopener">Biden COVID-19 Response Plan: Overview of Its Inherent Investment Themes</a>). Although the cold chain is fragmented and largely privately-held, but there are opportunities in three areas:<ol>
<li>
Freight and Logistics: Most listed companies fall into this category, including both integrated cold chain freight and logistics stocks, as well as niche players in either of freight or logistics.</li>
<li>
Freezer Manufacturers: Ultra-cold freezer boxes and related industrial components of various shapes and sizes are needed for the cold chain to function. Several stocks serve this segment.</li>
<li>
Specialty Chemicals: Dry ice gets all the headlines, as massive amounts are needed but supply is short, but other specialty chemicals and industrial gases are also needed in the cold chain.</li>
</ol>

COVID-19 vaccines figure into Biden's recently-announced COVID-19 response plan, though with a clear emphasis on distribution versus development (as was Trump's focus). Biden's prioritisation of vaccine distribution – and the US$25 billion earmarked for it – is a gift for "cold chain" stocks."Cold chain" refers to a complex temperature-controlled supply chain that is mission-critical to the distribution of COVID-19 vaccines. Critical, because vaccines require consistent ultra-cold storage from manufacture to needle-stick, otherwise those expensive vaccines become medical waste.This Insight looks at cold chain stocks as an investment theme inherent in Biden's COVID-19 plan (see Biden COVID-19 Response Plan: Overview of Its Inherent Investment Themes). Although the cold chain is fragmented and largely privately-held, but there are opportunities in three areas:

Freight and Logistics: Most listed companies fall into this category, including both integrated cold chain freight and logistics stocks, as well as niche players in either of freight or logistics.

Freezer Manufacturers: Ultra-cold freezer boxes and related industrial components of various shapes and sizes are needed for the cold chain to function. Several stocks serve this segment.

Specialty Chemicals: Dry ice gets all the headlines, as massive amounts are needed but supply is short, but other specialty chemicals and industrial gases are also needed in the cold chain.


Biden COVID-19 Response Plan: Cold Chain Transportation and Logistics Stocks Benefit

<ul><li>McKesson Corporation's second quarter fiscal 2025 results present a multidimensional view of the company's current financial standing and future prospects.</li><li>With reported record revenues of $93.7 billion, McKesson demonstrated a robust 21% year-over-year increase, driven significantly by the U.S. Pharmaceutical segment.</li><li>This sector alone witnessed a 23% revenue boost, underscored by the onboarding of a new strategic partner and broadened specialty product distribution.</li></ul>

McKesson Corporation's second quarter fiscal 2025 results present a multidimensional view of the company's current financial standing and future prospects.With reported record revenues of $93.7 billion, McKesson demonstrated a robust 21% year-over-year increase, driven significantly by the U.S. Pharmaceutical segment.This sector alone witnessed a 23% revenue boost, underscored by the onboarding of a new strategic partner and broadened specialty product distribution.

McKesson Corporation: Will Its Cost Optimization & Operational Efficiencies Help Alter The Playing Field? - Major Drivers

<ul><li>McKesson Corporation reported its earnings for the first quarter of fiscal 2025, showcasing continued growth and strategic progress across various aspects of its diversified healthcare services.</li><li>With a reported revenue of $79.3 billion, the company exhibited a 6% increase year-over-year, and an adjusted earnings per share increase of 8% to $7.88.</li><li>These figures surpassed initial expectations, prompting an upward revision of full-year adjusted earnings per share guidance from $31.25-$32.05 to $31.75-$32.55.</li></ul>

McKesson Corporation reported its earnings for the first quarter of fiscal 2025, showcasing continued growth and strategic progress across various aspects of its diversified healthcare services.With a reported revenue of $79.3 billion, the company exhibited a 6% increase year-over-year, and an adjusted earnings per share increase of 8% to $7.88.These figures surpassed initial expectations, prompting an upward revision of full-year adjusted earnings per share guidance from $31.25-$32.05 to $31.75-$32.55.

McKesson Corporation: Expanding Oncology & Specialty Pharmaceutical Services As Well As Distribution & Sourcing! - Major Drivers

United States

McKesson Corporation distributes pharmaceuticals, medical-surgical supplies, and health and beauty care products throughout North America. The Company also develops, implements, and supports software that facilitates the integration of data throughout the health enterprise. In addition, McKesson offers analytic, care management, and patient solutions for payers.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

McKesson (MCK UN)

Is McKesson Wall Street’s Safe Haven? How This Drug Giant Can Thrive In Uncertain Times!

As markets reel from the reimposition of tariffs on Mexico and Canada, investors are scrambling for stability in a landscape marked by global...

Baptista Research

McKesson Corporation: Growth in Prescription Technology Solutions (RxTS) to Solidify Its Competitive Advantage!

McKesson Corporation's third-quarter fiscal 2025 earnings call reveals a mix of robust financial performance and strategic advancements, balanced...

Baptista Research

Biden COVID-19 Response Plan: Cold Chain Transportation and Logistics Stocks Benefit

Biden's COVID-19 response plan earmarks US$25 billion to vaccines, but with a twist. His emphasis is vaccine distribution, not development. That...

Kyle Rudden

McKesson Corporation: Will Its Cost Optimization & Operational Efficiencies Help Alter The Playing Field? - Major Drivers

McKesson Corporation's second quarter fiscal 2025 results present a multidimensional view of the company's current financial standing and future...

Baptista Research

McKesson Corporation: Expanding Oncology & Specialty Pharmaceutical Services As Well As Distribution & Sourcing! - Major Drivers

McKesson Corporation reported its earnings for the first quarter of fiscal 2025, showcasing continued growth and strategic progress across various...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)